DK1394178T3 - Fremgangsmåde til fastlæggelse af den terapeutiske aktivitet af et MBP-fragment - Google Patents

Fremgangsmåde til fastlæggelse af den terapeutiske aktivitet af et MBP-fragment

Info

Publication number
DK1394178T3
DK1394178T3 DK03022727T DK03022727T DK1394178T3 DK 1394178 T3 DK1394178 T3 DK 1394178T3 DK 03022727 T DK03022727 T DK 03022727T DK 03022727 T DK03022727 T DK 03022727T DK 1394178 T3 DK1394178 T3 DK 1394178T3
Authority
DK
Denmark
Prior art keywords
mbp
residues
levels
amino acid
synthetic peptides
Prior art date
Application number
DK03022727T
Other languages
English (en)
Inventor
Kenneth G Warren
Ingrid Catz
Original Assignee
Univ Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alberta filed Critical Univ Alberta
Application granted granted Critical
Publication of DK1394178T3 publication Critical patent/DK1394178T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
DK03022727T 1997-04-04 1998-04-03 Fremgangsmåde til fastlæggelse af den terapeutiske aktivitet af et MBP-fragment DK1394178T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2201841A CA2201841C (en) 1997-04-04 1997-04-04 Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
PCT/CA1998/000290 WO1998045327A1 (en) 1997-04-04 1998-04-03 Peptide fragments of myelin basic protein, their pharmaceutical compositions and their use in treating multiple sclerosis

Publications (1)

Publication Number Publication Date
DK1394178T3 true DK1394178T3 (da) 2008-05-26

Family

ID=4160340

Family Applications (2)

Application Number Title Priority Date Filing Date
DK98914725T DK0970121T3 (da) 1997-04-04 1998-04-03 Peptidfragmenter af myelin-basisk-protein, deres farmaceutiske sammensætninger og deres anvendelse i behandling af multipel sklerose
DK03022727T DK1394178T3 (da) 1997-04-04 1998-04-03 Fremgangsmåde til fastlæggelse af den terapeutiske aktivitet af et MBP-fragment

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK98914725T DK0970121T3 (da) 1997-04-04 1998-04-03 Peptidfragmenter af myelin-basisk-protein, deres farmaceutiske sammensætninger og deres anvendelse i behandling af multipel sklerose

Country Status (21)

Country Link
EP (2) EP0970121B1 (da)
JP (1) JP4173557B2 (da)
AT (2) ATE400582T1 (da)
AU (1) AU751303B2 (da)
CA (2) CA2494338C (da)
CY (2) CY1107445T1 (da)
CZ (1) CZ299535B6 (da)
DE (2) DE69839694D1 (da)
DK (2) DK0970121T3 (da)
ES (2) ES2299657T3 (da)
HK (1) HK1063805A1 (da)
HU (1) HU226768B1 (da)
NO (1) NO325018B1 (da)
NZ (1) NZ338091A (da)
PL (1) PL191965B1 (da)
PT (2) PT970121E (da)
RO (1) RO119303B1 (da)
RU (1) RU2198893C2 (da)
SK (1) SK285815B6 (da)
UA (1) UA60331C2 (da)
WO (1) WO1998045327A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004536819A (ja) 2001-06-11 2004-12-09 トランジション・セラピューティックス・インコーポレーテッド ウイルス性、増殖性および炎症性の疾患の治療のためにビタミンｂ１２および治療薬を用いた複合治療
CN101353094B (zh) * 2008-09-22 2011-04-13 刘年路 密闭瓶状软塑料袋及其应用
AU2009354040A1 (en) 2009-10-12 2012-05-31 Lifebio Laboratories Llc Composition for treatment of Multiple Sclerosis
RU2646817C1 (ru) * 2016-12-27 2018-03-07 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Пептид из состава тяжелой цепи иммуноглобулина человека, пригодный для лечения рассеянного склероза

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
CA2053799C (en) * 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
ATE212358T1 (de) * 1992-04-09 2002-02-15 Autoimmune Inc Unterdrückung der proliferation von t-zellen mittels peptidfragmenten des basischen proteins aus myelin
US5824315A (en) * 1993-10-25 1998-10-20 Anergen, Inc. Binding affinity of antigenic peptides for MHC molecules
HUT77047A (hu) * 1994-10-25 1998-03-02 Immulogic Pharmaceutical Corporation Szklerózis multiplex kezelésére szolgáló készítmények és kezelések
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein

Also Published As

Publication number Publication date
SK132999A3 (en) 2000-06-12
EP0970121B1 (en) 2008-07-09
DE69839163T2 (de) 2009-02-12
ES2307317T3 (es) 2008-11-16
CA2201841A1 (en) 1998-10-04
EP1394178B1 (en) 2008-02-20
CA2201841C (en) 2010-01-26
DK0970121T3 (da) 2008-10-20
EP1394178A1 (en) 2004-03-03
NO994806L (no) 1999-12-06
HU226768B1 (en) 2009-09-28
NO325018B1 (no) 2008-01-14
PL191965B1 (pl) 2006-07-31
EP0970121A1 (en) 2000-01-12
SK285815B6 (sk) 2007-08-02
ATE386941T1 (de) 2008-03-15
CY1107445T1 (el) 2012-12-19
HUP0000812A3 (en) 2000-10-30
NO994806D0 (no) 1999-10-01
CA2494338C (en) 2007-07-17
CA2494338A1 (en) 1998-10-04
CZ299535B6 (cs) 2008-08-27
WO1998045327A1 (en) 1998-10-15
CZ9903464A3 (cs) 2000-11-15
AU751303B2 (en) 2002-08-15
RO119303B1 (ro) 2004-07-30
DE69839163D1 (de) 2008-04-03
DE69839694D1 (de) 2008-08-21
PL336085A1 (en) 2000-06-05
UA60331C2 (uk) 2003-10-15
HUP0000812A2 (hu) 2000-09-28
HK1063805A1 (en) 2005-01-14
AU6913098A (en) 1998-10-30
JP2001518885A (ja) 2001-10-16
CY1108239T1 (el) 2014-02-12
NZ338091A (en) 2001-10-26
ATE400582T1 (de) 2008-07-15
JP4173557B2 (ja) 2008-10-29
PT1394178E (pt) 2008-04-15
ES2299657T3 (es) 2008-06-01
PT970121E (pt) 2008-09-22
RU2198893C2 (ru) 2003-02-20

Similar Documents

Publication Publication Date Title
DK0789709T3 (da) Peptidspecificitet af anti-myelin basisprotein og administrationen af myelin basisproteinpeptider til dissemineret sklerose patienter
ATE425181T1 (de) Therapeutische zusammensetzungen aus antikorper und antisens nukleinsäuren gegen serrate
FI941860A0 (fi) Keskushermoston pesäkekovettumatautiaivo-selkäydinnesteestä peräisin olevan antimyeliiniemäsproteiinin synteettinen peptidispesifisyys
DK1394178T3 (da) Fremgangsmåde til fastlæggelse af den terapeutiske aktivitet af et MBP-fragment
WO1996018646A3 (en) Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
NZ335835A (en) Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients